newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences

- Seelos' SLS-002 is currently being developed specifically to treat the symptoms of suicidality associated with major depression NEW YORK, Aug. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan